Literature DB >> 16138849

Resistance to re-infection after exposure to normal and attenuated schistosome parasites in the baboon model.

T M Kariuki1, I O Farah.   

Abstract

The baboon model of schistosomiasis has been used extensively to study parasite biology, immune responses and pathological manifestations after natural and experimental infections. The body of knowledge accumulated so far has placed this animal model at the pinnacle in the continuing search for new interventions and might hold the key to the development of new anti-schistosome vaccines. In this review paper, we highlight previous and recent studies that have elevated the baboon to be the model of choice for schistosomiasis research. In particular, the long-term studies of re-infection after chemotherapy as well as the interaction between vaccination, chemotherapy and infection are highlighted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16138849     DOI: 10.1111/j.1365-3024.2005.00783.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  12 in total

1.  Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine.

Authors:  Weidong Zhang; Gul Ahmad; Workineh Torben; Zahid Noor; Loc Le; Raymond T Damian; Roman F Wolf; Gary L White; Maria Chavez-Suarez; Ronald B Podesta; Ronald C Kennedy; Afzal A Siddiqui
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

Review 2.  The Road to Elimination: Current State of Schistosomiasis Research and Progress Towards the End Game.

Authors:  Paul Ogongo; Ruth K Nyakundi; Gerald K Chege; Lucy Ochola
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

3.  Use of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons.

Authors:  Souvik Karmakar; Weidong Zhang; Gul Ahmad; Workineh Torben; Mayeen U Alam; Loc Le; Raymond T Damian; Roman F Wolf; Gary L White; David W Carey; Darrick Carter; Steven G Reed; Afzal A Siddiqui
Journal:  J Infect Dis       Date:  2014-01-16       Impact factor: 5.226

Review 4.  Current status of vaccines for schistosomiasis.

Authors:  Donald P McManus; Alex Loukas
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

5.  In the absence of CD154, administration of interleukin-12 restores Th1 responses but not protective immunity to Schistosoma mansoni.

Authors:  James P Hewitson; Paul A Hamblin; Adrian P Mountford
Journal:  Infect Immun       Date:  2007-05-07       Impact factor: 3.441

6.  Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model.

Authors:  Gul Ahmad; Weidong Zhang; Workineh Torben; Raymond T Damian; Roman F Wolf; Gary L White; Maria Chavez-Suarez; Ronald C Kennedy; Afzal A Siddiqui
Journal:  Vaccine       Date:  2009-03-10       Impact factor: 3.641

Review 7.  Experimental vaccines in animal models for schistosomiasis.

Authors:  Afzal A Siddiqui; Gul Ahmad; Raymond T Damian; Ronald C Kennedy
Journal:  Parasitol Res       Date:  2008-02-08       Impact factor: 2.289

8.  Upregulated expression of cytotoxicity-related genes in IFN-γ knockout mice with Schistosoma japonicum infection.

Authors:  Xiaotang Du; Jingjiao Wu; Meijuan Zhang; Yanan Gao; Donghui Zhang; Min Hou; Minjun Ji; Guanling Wu
Journal:  J Biomed Biotechnol       Date:  2011-10-01

9.  Dynamics of Th17 cells and their role in Schistosoma japonicum infection in C57BL/6 mice.

Authors:  Xiaoyun Wen; Lei He; Ying Chi; Sha Zhou; Jason Hoellwarth; Cui Zhang; Jifeng Zhu; Calvin Wu; Shawn Dhesi; Xuefeng Wang; Feng Liu; Chuan Su
Journal:  PLoS Negl Trop Dis       Date:  2011-11-15

10.  Population level changes in schistosome-specific antibody levels following chemotherapy.

Authors:  Mizuho Fukushige; Francisca Mutapi; Mark E J Woolhouse
Journal:  Parasite Immunol       Date:  2019-01       Impact factor: 2.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.